If you’re aware of “FOMO,” you’ll know that it stands for “fear of missing out.” It can be used to describe the feeling that many people have of wanting to experience everything that life has to offer. Sometimes FOMO can lead to people compromising their physical health by depriving…
Striking a Balance Between ‘YOLO’ and Practical Concerns with IPF
Fast weight loss in people with idiopathic pulmonary fibrosis (IPF), even after lung transplant, is linked with worse prognosis, and may indicate immune system activation, a study suggests. People who experience greater weight loss over a short period may be at greater risk for poor outcomes. The research, “…
April Kloxin, PhD, has received the 2019 National Institutes of Health (NIH) Director’s New Innovator Award to develop next-generation materials and tools to help accelerate research on idiopathic pulmonary fibrosis (IPF). Kloxin, a professor at the University of Delaware, is one of 60 researchers across the U.S. to win…
One of the reasons I enjoy traveling is its provided gift of reflection. While experiencing other cultures and countries, I ponder how I live my daily life. Since getting my idiopathic pulmonary fibrosis (IPF) diagnosis, my need for control and organization has increased. It is a way that I…
Scientists have found the mechanism by which a new mutation in the surfactant protein A1 (SFTPA1) gene leads to the onset and progression of idiopathic pulmonary fibrosis (IPF) in mice. Their findings were described in the study, “A homozygous SFTPA1 mutation drives necroptosis of type II alveolar…
My husband, Jonny, and I return to the University of Nevada, Reno, every year for our alumni rugby game. The first weekend of October is among the best of the year. Our parents come to watch, and for one magical day we have our closest friends and family in one…
A Japanese agency has cleared MediciNova’s request for a patent covering the use of its orally available candidates MN-001 (tipelukast) and MN-002 — a major metabolite of MN-001 — in treating idiopathic pulmonary fibrosis (IPF). The company announced it has received a Notice of Allowance from…
Our bodies are amazing machines, but we can be hard on them sometimes. My adventurous spirit has led to some accidents and injuries, but my body always prevails. When I push myself too far, my body forces me to rest, reminding…
New research provides important insights into the process of activation and formation of cells that are crucial for fibrosis to occur, uncovering potential targets that can help control fibrosis in chronic diseases such as pulmonary fibrosis (PF). Scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) discovered…
Final data from the PRAISE trial support the efficacy and safety of pamrevlumab, an investigational therapy for the treatment of idiopathic pulmonary fibrosis (IPF) being developed by FibroGen. Data showed that into-the-vein (intravenous) infusions of pamrevlumab reduced the decline in respiratory function by 60.3%. It also cut to…
